ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Martin Breuer
Bernhard M. Kemkes
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schütz, A.
Right arrow Articles by Kemkes, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schütz, A.
Right arrow Articles by Kemkes, B. M.

Ann Thorac Surg 1997;63:578-581
© 1997 The Society of Thoracic Surgeons

Current Review

Antimyosin Antibodies in Cardiac Rejection

Albert Schütz, MD, Martin Breuer, MD, Bernhard M. Kemkes, MD

Department of Cardiovascular Surgery, Klinikum Bogenhausen, Munich, Germany

The antimyosin antibody is often applied to find out scintigraphically whether myocarditis, myocardial infarction, or (recently) cardiac rejection is present. In the past, a lot of experimental work and clinical studies were done to determine its position, especially for the noninvasive detection of cardiac transplant rejection. Efforts are focused on comparing its diagnostic benefit with that of endomyocardial biopsy. The feasibility of rejection grading and diagnostic reliability are essential parts of this discussion. On the basis of large prospective clinical studies and the information from several experimental animal trials, some important findings can be assumed. Antimyosin scintigraphy after the application of indium 111–labeled antimyosin antibodies is a reliable tool to detect or exclude noninvasively cardiac rejection in adults and children. A distinction among three rejection intensities is possible, as confirmed by immunohistologic examinations. Antimyosin scintigraphy is an important noninvasive method for detecting cardiac rejection, with considerable advantages compared with endomyocardial biopsy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.